Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Receivables (2017 - 2025)

Puma Biotechnology's Receivables history spans 9 years, with the latest figure at $53.7 million for Q4 2025.

  • For Q4 2025, Receivables rose 67.61% year-over-year to $53.7 million; the TTM value through Dec 2025 reached $53.7 million, up 67.61%, while the annual FY2025 figure was $53.7 million, 67.61% up from the prior year.
  • Receivables reached $53.7 million in Q4 2025 per PBYI's latest filing, up from $33.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $54.6 million in Q3 2024 to a low of $23.8 million in Q3 2021.
  • Average Receivables over 5 years is $33.0 million, with a median of $30.9 million recorded in 2021.
  • Peak YoY movement for Receivables: surged 88.59% in 2024, then crashed 38.57% in 2025.
  • A 5-year view of Receivables shows it stood at $32.5 million in 2021, then increased by 24.05% to $40.4 million in 2022, then rose by 18.56% to $47.8 million in 2023, then plummeted by 33.08% to $32.0 million in 2024, then skyrocketed by 67.61% to $53.7 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Receivables are $53.7 million (Q4 2025), $33.6 million (Q3 2025), and $25.9 million (Q2 2025).